MedTrace Logo

Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3

NCT05210504 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-06-05

Study results available
· View outcomes & findings →

Summary

This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

L-Lysine

5g L-lysine in 50ml water, administered orally

DRUG

Normal Saline

Normal (0.9%) Saline

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Jane Ferguson, PhD · Vanderbilt University Medical Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-09
Primary Completion
2023-01-27
Completion
2023-01-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05210504 on ClinicalTrials.gov